Seres Therapeutics (MCRB) Total Current Liabilities (2014 - 2026)

Seres Therapeutics has reported Total Current Liabilities for 13 years, with the latest figure at $19.3 million in Q1 2026.

• Quarterly Total Current Liabilities fell 38.24% year-over-year to $19.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.3 million (down 38.24% YoY) and the FY2025 annual result came in at $19.3 million, down 53.13% from the prior year.
• Total Current Liabilities steadied at $19.3 million in Q1 2026 per MCRB's latest filing, from $19.3 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $108.3 million in Q2 2024 and troughed at $19.3 million in Q4 2025.
• A 5-year average of $64.4 million and a median of $77.9 million in 2023 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2025: Total Current Liabilities soared 72.07% in 2022, then slumped 71.43% in 2025.
• Over 5 years, Total Current Liabilities stood at $85.6 million in 2022, then gained by 15.26% to $98.7 million in 2023, then tumbled by 58.22% to $41.2 million in 2024, then slumped by 53.13% to $19.3 million in 2025, then climbed by 0.11% to $19.3 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $19.3 million, $19.3 million, and $22.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.